Claritev Corporation CTEV
26.63 USD +2.63 (+10.96%)
Nov 10, 2026, 1:23 PM EST
23.19 Day range 26.83
11.50 52-week range 61.22
- YTD
- -37.71%
- 1 year
- -53.96%
News
benzinga.com Claritev Q3 2026 Earnings Call Transcript Claritev (NYSE:CTEV) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Claritev Raises FY2026 Sales Guidance from $1.000B-$1.020B to $1.038B-$1.043B vs $1.014B Est Claritev (NYSE:CTEV) raises FY2026 sales outlook from $1.000 billion-$1.020 billion to $1.038 billion-$1.043 billion vs $1.014 billion estimate.
benzinga.com Claritev Q3 EPS $(3.64) Beats $(3.81) Estimate, Sales $268.311M Beat $256.129M Estimate Claritev (NYSE:CTEV) reported quarterly losses of $(3.64) per share which beat the analyst consensus estimate of $(3.81) by 4.46 percent. This is a 13.95 percent increase over losses of $(4.23) per…
globenewswire.com Claritev Corporation Reports Third Quarter 2026 Results MCLEAN, Va., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable,…
globenewswire.com Claritev Corporation Announces Participation in Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum MCLEAN, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data, and insights company, today announced that members of its…- benzinga.com Claritev Selected By General Dynamics Information Technology To Support The World Trade Center Health Program; Terms Not Disclosed The WTC Health Program is a limited federal health care program established under the James Zadroga 9/11 Health and Compensation Act of 2010 (Extended in 2015). It provides nationwide medical…
- benzinga.com Barclays Maintains Overweight on Claritev, Raises Price Target to $40 Barclays analyst Glen Santangelo maintains Claritev (NYSE:CTEV) with a Overweight and raises the price target from $28 to $40.
benzinga.com Claritev Expands Collaboration With Marpai To Launch Pre, Post- Payment Integrity Services To Health Plans Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that Marpai, Inc. (OTCQX:MRAI) has expanded its relationship with Claritev to bring…- benzinga.com Wells Fargo Maintains Equal-Weight on Claritev, Raises Price Target to $30 Wells Fargo analyst Stan Berenshteyn maintains Claritev (NYSE:CTEV) with a Equal-Weight and raises the price target from $22 to $30.
benzinga.com Claritev Analysts Raise Their Forecasts Following Q2 Earnings CTEV reported better-than-expected Q2 results and raised FY26 sales guidance. Analysts maintain Buy ratings with increased price targets.
benzinga.com Citigroup Maintains Buy on Claritev, Raises Price Target to $45 Citigroup analyst Daniel Grosslight maintains Claritev (NYSE:CTEV) with a Buy and raises the price target from $40 to $45.
benzinga.com Canaccord Genuity Maintains Buy on Claritev, Raises Price Target to $43 Canaccord Genuity analyst Richard Close maintains Claritev (NYSE:CTEV) with a Buy and raises the price target from $37 to $43.
benzinga.com Claritev Raises FY2026 Sales Guidance from $985.000M-$1.000B to $1.000B-$1.020B vs $993.511M Est Claritev (NYSE:CTEV) raises FY2026 sales outlook from $985.000 million-$1.000 billion to $1.000 billion-$1.020 billion vs $993.511 million estimate.
benzinga.com Claritev Q2 EPS $(3.49) Beats $(4.21) Estimate, Sales $257.478M Beat $244.813M Estimate Claritev (NYSE:CTEV) reported quarterly losses of $(3.49) per share which beat the analyst consensus estimate of $(4.21) by 17.1 percent. This is a 8.4 percent increase over losses of $(3.81) per…- benzinga.com Canaccord Genuity Maintains Buy on Claritev, Raises Price Target to $37 Canaccord Genuity analyst Richard Close maintains Claritev (NYSE:CTEV) with a Buy and raises the price target from $32 to $37.
- benzinga.com Claritev Says DOJ Closes Antitrust Grand Jury Probe, Confirms Company Not Under Criminal Investigation As stated in the Form 8-K filed on May 18, 2026, in August 2024 Claritev Corporation (the "Company") received a confidential grand jury subpoena issued by the Antitrust Division of the Department of…
benzinga.com 7 Health Care Stocks With Whale Alerts In Today's Session 
benzinga.com Claritev Q1 2026 Earnings Call Transcript - benzinga.com Canaccord Genuity Initiates Coverage On Claritev with Buy Rating, Announces Price Target of $32 Canaccord Genuity analyst Richard Close initiates coverage on Claritev (NYSE:CTEV) with a Buy rating and announces Price Target of $32.
benzinga.com The High-Yield Stocks the Smart Money Is Buying Right Now Smart credit team Ares Mgmt bought discounted BDCs aggressively in Q1 2026. They're not guessing but expressing conviction in 17 positions.
benzinga.com Claritev Corp Says Received DOJ Grand Jury Subpoena In August 2024 For Health Insurance Investigation, Denies Being Identified As Target Following Reported Probe Allegations An article published on Thursday, May 14, 2026 alleges that "DOJ launches criminal antitrust probe into Claritev." In August of 2024, Claritev Corporation (the "Company") received a confidential…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Claritev Raises FY2026 Sales Guidance from $980.000M-$1.000B to $985.000M-$1.000B vs $989.607M Est Claritev (NYSE:CTEV) raises FY2026 sales outlook from $980.000 million-$1.000 billion to $985.000 million-$1.000 billion vs $989.607 million estimate.
benzinga.com Claritev Q1 EPS $(4.41) Misses $(3.85) Estimate, Sales $244.678M Beat $236.389M Estimate Claritev (NYSE:CTEV) reported quarterly losses of $(4.41) per share which missed the analyst consensus estimate of $(3.85) by 14.55 percent. This is a 0.68 percent decrease over losses of $(4.38) per…- benzinga.com Barclays Initiates Coverage On Claritev with Overweight Rating, Announces Price Target of $28 Barclays analyst Glen Santangelo initiates coverage on Claritev (NYSE:CTEV) with a Overweight rating and announces Price Target of $28.
- benzinga.com Wells Fargo Maintains Equal-Weight on Claritev, Lowers Price Target to $22 Wells Fargo analyst Stan Berenshteyn maintains Claritev (NYSE:CTEV) with a Equal-Weight and lowers the price target from $30 to $22.
benzinga.com Alpha Buying: Following the Insiders Into a Volatile Market - benzinga.com Citigroup Maintains Buy on Claritev, Lowers Price Target to $21 Citigroup analyst Daniel Grosslight maintains Claritev (NYSE:CTEV) with a Buy and lowers the price target from $63 to $21.
benzinga.com Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com Guggenheim Maintains Buy on Claritev, Lowers Price Target to $38 Guggenheim analyst Jason Cassorla maintains Claritev (NYSE:CTEV) with a Buy and lowers the price target from $43 to $38.
- benzinga.com Wells Fargo Maintains Equal-Weight on Claritev, Lowers Price Target to $30 Wells Fargo analyst Stan Berenshteyn maintains Claritev (NYSE:CTEV) with a Equal-Weight and lowers the price target from $33 to $30.
benzinga.com Claritev Q4 Earnings Summary & Key Takeaways - benzinga.com Claritev Q4 EPS $(4.88) Misses $(4.72) Estimate, Sales $246.554M Beat $241.025M Estimate Claritev (NYSE:CTEV) reported quarterly losses of $(4.88) per share which missed the analyst consensus estimate of $(4.72) by 3.39 percent. This is a 5.43 percent increase over losses of $(5.16) per…
benzinga.com Earnings Scheduled For February 23, 2026 
benzinga.com A Peek at Claritev's Future Earnings - benzinga.com Claritev Signs Agreement With Kinetiq Health To Enhance Cost Management, Advance Claims Surveillance Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent, and fair for all, today announced a…
- benzinga.com Citigroup Maintains Buy on Claritev, Lowers Price Target to $63 Citigroup analyst Daniel Grosslight maintains Claritev (NYSE:CTEV) with a Buy and lowers the price target from $80 to $63.
- benzinga.com Wells Fargo Initiates Coverage On Claritev with Equal-Weight Rating, Announces Price Target of $33 Wells Fargo analyst Stan Berenshteyn initiates coverage on Claritev (NYSE:CTEV) with a Equal-Weight rating and announces Price Target of $33.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com CORRECTION: Claritev Launches Public Offering Of 1.5M Shares By Hellman & Friedman Affiliates Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Earnings Scheduled For November 7, 2025 - benzinga.com Claritev Q3 EPS $(4.23) Misses $(3.38) Estimate, Sales $245.959M Beat $235.806M Estimate Claritev (NYSE:CTEV) reported quarterly losses of $(4.23) per share which missed the analyst consensus estimate of $(3.38) by 25.15 percent. This is a 128.65 percent decrease over losses of $(1.85)…
- benzinga.com Claritev's Earnings: A Preview
- benzinga.com Claritev Corporation Announces Strategic Investment In Klaim To Launch A Co-Branded Payment Acceleration Service Within Claritev's Provider Network Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a global leader in healthcare analytics and claims analysis, today announced a strategic investment in Klaim, Inc., an AI-driven…
- benzinga.com Citigroup Upgrades Claritev to Buy, Raises Price Target to $74 Citigroup analyst Daniel Grosslight upgrades Claritev (NYSE:CTEV) from Neutral to Buy and raises the price target from $55 to $74.
benzinga.com This Nextracker Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday